title: Fragment-to-Lead Medicinal Chemistry Publications in 2015.
abstract: Fragment-based drug discovery (FBDD) is now well-established as a technology for generating new chemical leads and drugs. This Miniperspective provides a tabulated overview of the fragment-to-lead literature published in the year 2015, together with a commentary on trends observed across the FBDD field during this time. It is hoped that this tabulated summary will provide a useful point of reference for both FBDD practitioners and the wider medicinal chemistry community.
authors.affiliation: Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, United Kingdom.
authors.forename: Christopher N
authors.initials: CN
authors.lastname: Johnson
authors.affiliation: Carmot Therapeutics Inc. , 409 Illinois Street, San Francisco, California 94158, United States.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Erlanson
authors.affiliation: Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, United Kingdom.
authors.forename: Christopher W
authors.initials: CW
authors.lastname: Murray
authors.affiliation: Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, United Kingdom.
authors.forename: David C
authors.initials: DC
authors.lastname: Rees
mesh_terms: D002626:Chemistry, Pharmaceutical; D055808:Drug Discovery; D011643:Publishing